Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.

Q1 Medicine
Skin therapy letter Pub Date : 2025-03-01
Austinn C Miller, Abigail E Watson, Marc J Inglese
{"title":"Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.","authors":"Austinn C Miller, Abigail E Watson, Marc J Inglese","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 2","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.

罗氟司特治疗脂溢性皮炎的研究进展。
脂溢性皮炎(SD)是一种慢性炎症性皮肤病,最常见于皮脂腺丰富的区域,如头皮、面部、腋窝和腹股沟。有几个因素可以促进SD的发展,如马拉色菌的定植、脂细胞活性、免疫力受损和环境影响。局部抗真菌药物、皮质类固醇和钙调磷酸酶抑制剂是目前治疗SD的主要方法。最近的临床试验证实了非甾体罗氟司特0.3%泡沫治疗SD的疗效。在这篇综述中,我们分析了0.3%罗氟司特泡沫的安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Skin therapy letter
Skin therapy letter Medicine-Medicine (all)
CiteScore
2.80
自引率
0.00%
发文量
0
期刊介绍: The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信